Abstract 1543P
Background
Immunotherapy is effective in treating unresectable oesophageal squamous cell carcinoma (ESCC). This study aims to evaluate the clinical efficacy and safety of neoadjuvant camrelizumab combined with docetaxel and carboplatin in locally advanced ESCC.
Methods
All patients underwent surgery within 4-8 weeks after receiving 2 cycles of neoadjuvant therapy, which was camrelizumab (200mg IV Q3W) combined with docetaxel (75 mg/m2 IV Q3W) and carboplatin (AUC= 5-6 IV Q3W). The pathological complete response (pCR) rate was the primary endpoint, and the secondary endpoints included R0 resection rate, objective response rate (ORR), disease-free survival (DFS), overall survival (OS) and safety.
Results
A total of 40 patients were included, of which 37 patients were evaluated, including 9 cases of complete response (CR), 18 cases of partial response (PR), 10 cases of stable disease (SD), and the ORR was 73% (27/37). The main adverse events were ALT/AST increase 52.5% (21/40), leukopenia 50% (20/40), nausea and vomiting 47.5% (19/40), bilirubin increase 40% (16/40), all of which were grade 1-2. One patient had Guillain-Barre Syndrome. Among these patients, 31 underwent surgical treatment, pCR rate was 22.6% (7/31), R0 resection rate was 100% (31/31), tumour regression grade (TRG) 0, 1, 2 and 3 were 22.6% (7/31), 16.1% (5/31), 22.6% (7/31) and 38.7% (12/31), respectively. The average operation time (310.0±57.6 minutes). The average intraoperative blood loss (136.1±41.4 ml) and the average hospitalization time after operation (10.9±2.7 days). The average number of resected lymph nodes (24.4±8.2). Surgery-related complications: anastomotic leakage 6.5% (2/31), pleural effusion 6.5% (2/31), cardiac arrhythmia 9.7% (3/31), pneumonia 3.2% (1/31), gastric emptying disorder 3.2% (1/31). The median follow-up time was 12 months (range 1–32 months). One patient had liver metastasis 21 months after surgery. No treatment-related death occurred.
Conclusions
Camrelizumab combined with docetaxel and carboplatin is effective and safe in the neoadjuvant treatment of locally advanced ESCC.
Clinical trial identification
ChiCTR2000033252.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1542P - Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
Presenter: Mingfang Xu
Session: Poster session 21
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Presenter: Xin fang Hou
Session: Poster session 21
1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presenter: Yuexiao Qi
Session: Poster session 21
1546P - Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Presenter: Hidekazu Hirano
Session: Poster session 21
1547P - SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Presenter: Chiaki Inagaki
Session: Poster session 21
1549P - A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Presenter: Hiroyuki Takeda
Session: Poster session 21
1551P - Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer
Presenter: Choong-kun Lee
Session: Poster session 21
1552P - Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Presenter: Tania Fleitas
Session: Poster session 21
1553P - Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study
Presenter: Benthe Doeve
Session: Poster session 21